OcuHeal LNP Technology Licensing Solutions
OcuHeal™ is a highly efficient eye-drop delivery mechanism to maximize drug delivery to deeper ocular tissues. We invite collaborations with pharmaceutical companies to render repurposed drugs IP-protectable with this proprietary drug delivery licensable technology. With multiple billion-dollar drug products going off-patent, a 505(b)(2) regulatory strategy presents a cost-effective way to develop an extended product life cycle with novel IP. Contact us for a discussion.
90% Of All Commercial Eyedrops Are Highly Inefficient
The Problem
- <95% of each eye drop is lost by naso-lacrimal drainage
- Some critical eye medications are drug suspensions, not solutions
- Drug suspensions lead to “graininess” on the ocular surface à feeling of “sand in the eye”
- Higher drug concentrations needed for efficacyà leads to side effects and higher systemic drug presence
- Issues of non-biocompatibility (pH, “sting”)
UnMet Clinical Need
- Efficient, immediate drug absorption upon instillation of eye-drop
- Optimized residence time of eye-drop
- Optimize viscosity (enhance without causing blurred vision)
- Optimize contact angle (minimize)
- Optimize surface tension
- Dissolved drug will enable immediate bioavailability
- Immediate permeation of ocular mucosa into cornea
Introducing OcuHeal™ Lipid Nanoparticles
A highly efficient eye-drop delivery mechanism to maximize drug delivery to deeper ocular tissues
OcuHeal™ Lipid Nanoparticles features
- Rapid Tissue Penetration
- Fully Dissolved Drug
- Nanosized < 150 nm
- Non-settling
- Mucosa-Penetrating
- Safe and Tolerable – OcuHeal™ contains excipients that are in approved ophthalmic medications.
- Enabled technology for multiple drugs
- Applicable to other routes
Fully Dissolved Drug, Nano-Sized, Non-aggregating, Preservative-Free, Non-Settling
Characteristics | Attribute |
Fully Dissolved Drug | Yes |
Particle Size Distribution (PSD) | D50 : < 200 nm |
Stable | RT |
Settling | Non-settling |
Preservative | No preservative |
Container closure | Multi-dose |
Multi-Dose, Non-Settling, Non-Aggregating, Preservative-Free
Time | D10 (µm) | D50 (µm) | D90 (µm) |
T=0 | 0.089 | 0.142 | 0.215 |
T=180d | 0.086 | 0.138 | 0.209 |
T=360d | 0.088 | 0.140 | 0.213 |
OcuHeal™ Patent Granted in Global Jurisdictions
Platform Delivery System: API- in- OcuHeal™Lipid Nanoparticles Eye-Drops Have a Flexible Composition of Lipid Excipients, Flexible Range of Sizes, Flexible Range of Lipid / Aqueous, Wide Portfolio of Drug Types, Scalable and Simple Manufacturing Process
- Fully Patented
- Technology applicable to multiple routes
- Wholly owned by Symphony parent company, Integral BioSystems
- Broad IP scope
- Both Composition and Process IP
- Patented in USA, Canada, Great Britain, France, Italy, Germany, Spain, India, Singapore, China, Japan, Australia, New Zealand, South Africa